DOCSLIB.ORG

Antimony(V) Sulfide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimony(V) Sulfide Antimony(V) sulfide sc-233886 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Antimony(V) sulfide STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH1 HAZARD INSTABILITY1 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS Sb2-S5, "antimony sulphide", "antimonial saffron", "antimonic sulfide", "antimony red", "antimony sulfide golden", "C.I. 77061", "golden antimony sulfide" Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 3 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 0 Moderate=2 High=3 Chronic: 2 Extreme=4 CANADIAN WHMIS SYMBOLS 1 of 8 EMERGENCY OVERVIEW RISK Harmful by inhalation and if swallowed. Highly flammable. Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Antimony poisoning causes similar symptoms to arsenic poisoning although vomiting is more prominent. There may be changes in the rhythm of the heart beat. ! If ingested, sulfide salts can form hydrogen sulfide, causing headache, cyanosis, low blood pressure, loss of consciousness, tremors and convulsions. EYE ! Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result. SKIN ! There is some evidence to suggest that this material can cause inflammation of the skin on contact in some persons. ! Skin contact with antimony compounds may result in redness and severe irritation with the formation of itchy papules, pustules, skin lesions/ small septic blisters (antimony spots) within a few hours. Rhinitis may also result from dermal contact. ! Open cuts, abraded or irritated skin should not be exposed to this material. ! Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. INHALED ! Inhalation of dusts, generated by the material, during the course of normalhandling, may be harmful. ! The material is not thought to produce respiratory irritation (as classified using animal models). Nevertheless inhalation of dusts, or fume, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress. ! Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled. ! Inhalation of antimony can cause breathing difficulties and gastrointestinal upset including sore throat, shallow breathing, dizziness, weight loss, gum bleeds and anemia. Lung swelling and congestion can occur. CHRONIC HEALTH EFFECTS ! There has been some concern that this material can cause cancer or mutations but there is not enough data to make an assessment. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung. Repeated or prolonged exposure to antimony and its compounds may produce inflammation of the mouth cavity, dry throat, metallic taste, gum infection, perforation of the nasal septum and throat, laryngitis, headache, difficulty breathing, indigestion, nausea, vomiting, diarrhea, loss of appetite, anemia, weight loss, tightness and pain in the chest, sleeplessness, muscular pain and weakness, dizziness, pharyngitis, bronchitis and pneumonia. Degenerative changes of the liver and kidney may occur. Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS NAME CAS RN % antimony pentasulfide 1315-04-4 >95 Section 4 - FIRST AID MEASURES SWALLOWED " IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. " Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise: EYE ! If this product comes in contact with the eyes: " Wash out immediately with fresh running water. " Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. SKIN ! If skin contact occurs: " Immediately remove all contaminated clothing, including footwear " Flush skin and hair with running water (and soap if available). INHALED " If fumes or combustion products are inhaled remove from contaminated area. " Lay patient down. Keep warm and rested. NOTES TO PHYSICIAN 2 of 8 " Chelation with British Anti-Lewisite (BAL) for serious antimony exposures should be employed. " Dialyse as needed. The role of exchange diffusion is not clear. For exposures involving sulfides and hydrogen sulfide (including gastric acid decomposition products of alkaline sulfides). " Hydrogen sulfide anion produces its major toxic effect through inhibition of cytochrome oxidases. " Symptoms include profuse salivation, nausea, vomiting and diarrhea. Central nervous effects may include giddiness, headache, vertigo, amnesia, confusion and unconsciousness. Tachypnea, palpitation, tachycardia, arrhythmia, sweating, weakness and muscle cramps may also indicate over-exposures. Section 5 - FIRE FIGHTING MEASURES Vapour Pressure (mmHG): Negligible Upper Explosive Limit (%): Not available Specific Gravity (water=1): 4.12 Lower Explosive Limit (%): Not available EXTINGUISHING MEDIA ! For SMALL FIRES: Dry chemical, CO2, water spray or foam. For LARGE FIRES: Water-spray, fog or foam. FIRE FIGHTING " Alert Emergency Responders and tell them location and nature of hazard. " Wear breathing apparatus plus protective gloves. When any large container (including road and rail tankers) is involved in a fire, consider evacuation by 1000 metres in all directions. GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS " Flammable solid which burns and propagates flame easily, even when partly wetted with water. " Any source of ignition, i.e. friction, heat, sparks or flame, may cause fire or explosion. Decomposition may produce toxic fumes of: sulfur oxides (SOx), hydrogen sulfide (H2S), metal oxides. FIRE INCOMPATIBILITY ! None known. PERSONAL PROTECTION Glasses: Chemical goggles. Gloves: Respirator: Particulate dust filter. Section 6 - ACCIDENTAL RELEASE MEASURES MINOR SPILLS " Remove all ignition sources. " DO NOT touch or walk through spilled material. MAJOR SPILLS " Clear area of personnel and move upwind. " Alert Emergency Responders and tell them location and nature of hazard. Section 7 - HANDLING AND STORAGE PROCEDURE FOR HANDLING " Avoid all personal contact, including inhalation. " Wear protective clothing when risk of overexposure occurs. RECOMMENDED STORAGE METHODS ! For low viscosity materials and solids: Drums and jerricans must be of the non-removable head type. Where a can is to be used as an inner package, the can must have a screwed enclosure. STORAGE REQUIREMENTS ! FOR MINOR QUANTITIES: " Store in an indoor fireproof cabinet or in a room of noncombustible construction " Provide adequate portable fire-extinguishers in or near the storage area. Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION EXPOSURE CONTROLS TWA STEL Peak Source Material TWA ppm STEL ppm Peak ppm TWA F/CC Notes mg/m# mg/m# mg/m# 3 of 8 ___________ ___________ _______ _______ _______ _______ _______ _______ _______ _______ antimony Canada - British pentasulfide Columbia (Antimony and 0.5 Occupational compounds, as Exposure Limits Sb) antimony US - Minnesota pentasulfide Permissible (Antimony and 0.5 Exposure Limits compounds (as (PELs) Sb)) antimony Canada - Alberta pentasulfide Occupational (Antimony & 0.5 Exposure Limits compounds, as Sb) Canada - Quebec antimony Permissible pentasulfide Exposure Values (Antimony, metal 0.5 for Airborne and compounds Contaminants (as Sb)) (English) antimony US OSHA pentasulfide Permissible (Antimony and 0.5 Exposure Levels compounds (as (PELs) - Table Z1 Sb)) US - Vermont Permissible antimony Exposure Limits pentasulfide Table Z-1-A (Antimony and 0.5 Transitional Limits compounds (as for Air Sb)) Contaminants US - Vermont antimony Permissible pentasulfide Exposure Limits (Antimony and 0.5 Table Z-1-A Final compounds (as Rule Limits for Air Sb)) Contaminants US - Tennessee antimony Occupational pentasulfide Exposure Limits - (Antimony and 0.5 Limits For Air compounds (as Contaminants Sb)) US - California antimony Permissible pentasulfide Exposure Limits (Antimony and 0.5 for Chemical compounds, as Contaminants Sb) antimony US - Idaho - Limits pentasulfide for Air (Antimony and 0.5 Contaminants compounds (as Sb)) antimony US - Hawaii Air pentasulfide Contaminant (Antimony and 0.5 Limits compounds (as Sb)) antimony US - Alaska Limits pentasulfide for Air (Antimony and 0.5 Contaminants compounds
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 123. Antimony
    1998:11 The Nordic Expert Group for Criteria Documentation of Health Risks from Chemicals 123. Antimony John Erik Berg Knut Skyberg Nordic Council of Ministers arbete och hälsa vetenskaplig skriftserie ISBN 91–7045–471–x ISSN 0346–7821 http://www.niwl.se/ah/ah.htm National Institute for Working Life National Institute for Working Life The National Institute for Working Life is Sweden's center for research and development on labour market, working life and work environment. Diffusion of infor- mation, training and teaching, local development and international collaboration are other important issues for the Institute. The R&D competence will be found in the following areas: Labour market and labour legislation, work organization and production technology, psychosocial working conditions, occupational medicine, allergy, effects on the nervous system, ergonomics, work environment technology and musculoskeletal disorders, chemical hazards and toxicology. A total of about 470 people work at the Institute, around 370 with research and development. The Institute’s staff includes 32 professors and in total 122 persons with a postdoctoral degree. The National Institute for Working Life has a large international collaboration in R&D, including a number of projects within the EC Framework Programme for Research and Technology Development. ARBETE OCH HÄLSA Redaktör: Anders Kjellberg Redaktionskommitté: Anders Colmsjö och Ewa Wigaeus Hjelm © Arbetslivsinstitutet & författarna 1998 Arbetslivsinstitutet, 171 84 Solna, Sverige ISBN 91–7045–471–X ISSN 0346-7821 Tryckt hos CM Gruppen Preface The Nordic Council is an intergovernmental collaborative body for the five countries, Denmark, Finland, Iceland, Norway and Sweden. One of the committees, the Nordic Senior Executive Committee for Occupational Environmental Matters, initiated a project in order to produce criteria documents to be used by the regulatory authorities in the Nordic countries as a scientific basis for the setting of national occupational exposure limits.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Chemical Names and CAS Numbers Final
    Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number C3H8O 1‐propanol C4H7BrO2 2‐bromobutyric acid 80‐58‐0 GeH3COOH 2‐germaacetic acid C4H10 2‐methylpropane 75‐28‐5 C3H8O 2‐propanol 67‐63‐0 C6H10O3 4‐acetylbutyric acid 448671 C4H7BrO2 4‐bromobutyric acid 2623‐87‐2 CH3CHO acetaldehyde CH3CONH2 acetamide C8H9NO2 acetaminophen 103‐90‐2 − C2H3O2 acetate ion − CH3COO acetate ion C2H4O2 acetic acid 64‐19‐7 CH3COOH acetic acid (CH3)2CO acetone CH3COCl acetyl chloride C2H2 acetylene 74‐86‐2 HCCH acetylene C9H8O4 acetylsalicylic acid 50‐78‐2 H2C(CH)CN acrylonitrile C3H7NO2 Ala C3H7NO2 alanine 56‐41‐7 NaAlSi3O3 albite AlSb aluminium antimonide 25152‐52‐7 AlAs aluminium arsenide 22831‐42‐1 AlBO2 aluminium borate 61279‐70‐7 AlBO aluminium boron oxide 12041‐48‐4 AlBr3 aluminium bromide 7727‐15‐3 AlBr3•6H2O aluminium bromide hexahydrate 2149397 AlCl4Cs aluminium caesium tetrachloride 17992‐03‐9 AlCl3 aluminium chloride (anhydrous) 7446‐70‐0 AlCl3•6H2O aluminium chloride hexahydrate 7784‐13‐6 AlClO aluminium chloride oxide 13596‐11‐7 AlB2 aluminium diboride 12041‐50‐8 AlF2 aluminium difluoride 13569‐23‐8 AlF2O aluminium difluoride oxide 38344‐66‐0 AlB12 aluminium dodecaboride 12041‐54‐2 Al2F6 aluminium fluoride 17949‐86‐9 AlF3 aluminium fluoride 7784‐18‐1 Al(CHO2)3 aluminium formate 7360‐53‐4 1 of 75 Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number Al(OH)3 aluminium hydroxide 21645‐51‐2 Al2I6 aluminium iodide 18898‐35‐6 AlI3 aluminium iodide 7784‐23‐8 AlBr aluminium monobromide 22359‐97‐3 AlCl aluminium monochloride
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • SDS) Antimony Pentasulfide
    Safety Data Sheet (SDS) Antimony Pentasulfide 1.CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Substance name(Product name): Antimony Pentasulfide (AS-S1) Company name: NIHON SEIKO CO.,LTD. Address 3-2 SHIMOMIYABI-CHO SHINJUKU-KU TOKYO 162-0822 JAPAN Charge section NIHON SEIKO CO.,LTD. SALES SECTION Phone number +81-3-3235-0031 Fax number +81-3-3235-0034 E-mail address [email protected] Emergency telephone number NIHON SEIKO CO.,LTD. NAKASE REFINERY QUALITY ASSURANCE SECTION +81-79-667-2121 Recommended use and restriction on use: Industrial materials: Surface preparation agent of Metal, etc. 2.HAZARDS IDENTIFICATION GHS classification： Physical hazards :Out of category (Not classified) Health hazards Acute Toxicity (Oral) :Classification not possible Acute Toxicity (Dermal) :Classification not possible Acute Toxicity (Inhalation: dust/mist） :Classification not possible Acute Toxicity (Inhalation: fume/vapors） :Out of category Skin corrosion/irritation :Classification not possible Serious eye danger/eye irritation :Classification not possible Respiratory sensitization :Classification not possible Skin sensitization :Classification not possible Germ cell mutagenicity :Classification not possible Carcinogenicity :Classification not possible Reproductive toxicity :Classification not possible Specific target organ systemic toxicity (Single exposure) :Classification not possible Specific target organ systemic toxicity (Repeated exposure) :Classification not possible Aspiration hazard :Classification not possible Environmental hazards Hazardous to the aquatic environment (Acute) :Classification not possible Hazardous to the aquatic environment (Chronic) :Classification not possible Hazardous to the ozone layer :Not classified Antimony Pentasulfide Issue No: Q0782-00 Issue Date: July 03, 2013 Page 1 of 7 GHS label: Hazard pictogram Not applicable. Signal word Not applicable. Hazard statements Not applicable. Precautionary statements 【Prevention】 Not applicable.
    [Show full text]
  • An Access-Dictionary of Internationalist High Tech Latinate English
    An Access-Dictionary of Internationalist High Tech Latinate English Excerpted from Word Power, Public Speaking Confidence, and Dictionary-Based Learning, Copyright © 2007 by Robert Oliphant, columnist, Education News Author of The Latin-Old English Glossary in British Museum MS 3376 (Mouton, 1966) and A Piano for Mrs. Cimino (Prentice Hall, 1980) INTRODUCTION Strictly speaking, this is simply a list of technical terms: 30,680 of them presented in an alphabetical sequence of 52 professional subject fields ranging from Aeronautics to Zoology. Practically considered, though, every item on the list can be quickly accessed in the Random House Webster’s Unabridged Dictionary (RHU), updated second edition of 2007, or in its CD – ROM WordGenius® version. So what’s here is actually an in-depth learning tool for mastering the basic vocabularies of what today can fairly be called American-Pronunciation Internationalist High Tech Latinate English. Dictionary authority. This list, by virtue of its dictionary link, has far more authority than a conventional professional-subject glossary, even the one offered online by the University of Maryland Medical Center. American dictionaries, after all, have always assigned their technical terms to professional experts in specific fields, identified those experts in print, and in effect held them responsible for the accuracy and comprehensiveness of each entry. Even more important, the entries themselves offer learners a complete sketch of each target word (headword). Memorization. For professionals, memorization is a basic career requirement. Any physician will tell you how much of it is called for in medical school and how hard it is, thanks to thousands of strange, exotic shapes like <myocardium> that have to be taken apart in the mind and reassembled like pieces of an unpronounceable jigsaw puzzle.
    [Show full text]
  • La Oroya Metallurgical Complex
    COMPLEMENTARY HUMAN HEALTH RISK ASSESSMENT La Oroya Metallurgical Complex Prepared for Doe Run Peru Victor Andres Belaunde 147 Torre Real 3, Piso 9, San Isidro Lima, Peru Prepared by 7900 SE 28th Street Suite 410 Mercer Island, WA 98040 November 21, 2008 Complementary Human Health Risk Assessment La Oroya Metallurgical Complex November 21, 2008 CONTENTS LIST OF FIGURES...................................................................................................................................vi LIST OF TABLES ..................................................................................................................................viii ACRONYMS AND ABBREVIATIONS...............................................................................................xi GLOSSARY OF TERMS .......................................................................................................................xiv EXECUTIVE SUMMARY ................................................................................................................... xvii 1 INTRODUCTION ...........................................................................................................................1‐1 1.1 RISK ASSESSMENT APPROACH AND SCOPE .............................................................1‐1 1.2 SUMMARY OF THE 2005 RISK ASSESSMENT...............................................................1‐2 1.3 REPORT ORGANIZATION ................................................................................................1‐4 2 SITE CHARACTERIZATION.......................................................................................................2‐1
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen Et Al
    US008821928B2 (12) United States Patent (10) Patent No.: US 8,821,928 B2 Hemmingsen et al. (45) Date of Patent: Sep. 2, 2014 (54) CONTROLLED RELEASE 5,869,097 A 2/1999 Wong et al. PHARMACEUTICAL COMPOSITIONS FOR 6,103,261 A 8, 2000 Chasin et al. 2003.01.18641 A1 6/2003 Maloney et al. PROLONGED EFFECT 2003/O133976 A1* 7/2003 Pather et al. .................. 424/466 2004/O151772 A1 8/2004 Andersen et al. (75) Inventors: Pernille Hoyrup Hemmingsen, 2005.0053655 A1 3/2005 Yang et al. Bagsvaerd (DK); Anders Vagno 2005/O158382 A1* 7/2005 Cruz et al. .................... 424/468 2006, O1939 12 A1 8, 2006 KetSela et al. Pedersen, Virum (DK); Daniel 2007/OOO3617 A1 1/2007 Fischer et al. Bar-Shalom, Kokkedal (DK) 2007,0004797 A1 1/2007 Weyers et al. (73) Assignee: Egalet Ltd., London (GB) 2007. O190142 A1 8, 2007 Breitenbach et al. (Continued) (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 1052 days. DE 202006O14131 1, 2007 EP O435,726 8, 1991 (21) Appl. No.: 12/602.953 (Continued) (22) PCT Filed: Jun. 4, 2008 OTHER PUBLICATIONS (86). PCT No.: PCT/EP2008/056910 Krogel etal (Pharmaceutical Research, vol. 15, 1998, pp. 474-481).* Notification of Transmittal of the International Search Report and the S371 (c)(1), Written Opinion of the International Searching Authority issued Jul. (2), (4) Date: Jun. 7, 2010 8, 2008 in International Application No. PCT/DK2008/000016. International Preliminary Reporton Patentability issued Jul.
    [Show full text]
  • Diccionario Del Sistema De Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS
    DIRECCION GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS - DIGEMID EQUIPO DE ASESORIA - AREA DE CATALOGACION Diccionario del Sistema de Clasificación Anatómica, Terapéutica, Química - ATC CATALOGO SECTORIAL DE PRODUCTOS FARMACEUTICOS CODIGO DESCRIPCION ATC EN CASTELLANO DESCRIPCION ATC EN INGLES FUENTE A TRACTO ALIMENTARIO Y METABOLISMO ALIMENTARY TRACT AND METABOLISM ATC OMS A01 PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01A PREPARADOS ESTOMATOLÓGICOS STOMATOLOGICAL PREPARATIONS ATC OMS A01AA Agentes para la profilaxis de las caries Caries prophylactic agents ATC OMS A01AA01 Fluoruro de sodio Sodium fluoride ATC OMS A01AA02 Monofluorfosfato de sodio Sodium monofluorophosphate ATC OMS A01AA03 Olaflur Olaflur ATC OMS A01AA04 Fluoruro de estaño Stannous fluoride ATC OMS A01AA30 Combinaciones Combinations ATC OMS A01AA51 Fluoruro de sodio, combinaciones Sodium fluoride, combinations ATC OMS A01AB Antiinfecciosos y antisépticos para el tratamiento oral local Antiinfectives and antiseptics for local oral treatment ATC OMS A01AB02 Peróxido de hidrógeno Hydrogen peroxide ATC OMS A01AB03 Clorhexidina Chlorhexidine ATC OMS A01AB04 Amfotericina B Amphotericin B ATC OMS A01AB05 Polinoxilina Polynoxylin ATC OMS A01AB06 Domifeno Domiphen ATC OMS A01AB07 Oxiquinolina Oxyquinoline ATC OMS A01AB08 Neomicina Neomycin ATC OMS A01AB09 Miconazol Miconazole ATC OMS A01AB10 Natamicina Natamycin ATC OMS A01AB11 Varios Various ATC OMS A01AB12 Hexetidina Hexetidine ATC OMS A01AB13 Tetraciclina Tetracycline ATC OMS A01AB14 Cloruro de benzoxonio
    [Show full text]
  • Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126)
    Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126) Appendix X - List of Chemical Names and Common Names for Hazardous Wastes and Hazardous Materials (a) This subdivision sets forth a list of chemicals which create a presumption that a waste is a hazardous waste. If a waste consists of or contains a chemical listed in this subdivision, the waste is presumed to be a hazardous waste Environmental Regulations of CALIFORNIA unless it is determined that the waste is not a hazardous waste pursuant to the procedures set forth in section 66262.11. The hazardous characteristics which serve as a basis for listing the chemicals are indicated in the list as follows: (X) toxic (C) corrosive (I) ignitable (R) reactive * =Extremely Hazardous A chemical denoted with an asterisk is presumed to be an extremely hazardous waste unless it does not exhibit any of the criteria set forth in section 66261.110 and section 66261.113. Trademark chemical names are indicated by all capital letters. 1. Acetaldehyde (X,I) 2. Acetic acid (X,C,I) 3. Acetone, Propanone (I) 4. *Acetone cyanohydrin (X) 5. Acetonitrile (X,I) 6. *2-Acetylaminofluorene, 2-AAF (X) 7. Acetyl benzoyl peroxide (X,I,R) 8. *Acetyl chloride (X,C,R) 9. Acetyl peroxide (X,I,R) 10. Acridine (X) 11. *Acrolein, Aqualin (X,I) 12. *Acrylonitrile (X,I) 13. *Adiponitrile (X) 14. *Aldrin; 1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4,5,8-endo-exodimethanonaphthlene (X) 15. *Alkyl aluminum chloride (C,I,R) 16. *Alkyl aluminum compounds (C,I,R) 17.
    [Show full text]
  • Draft Report on Carcinogens Monograph on Antimony Trioxide
    Draft Report on Carcinogens Monograph on Antimony Trioxide Peer-Review Draft November 29, 2017 Office of the Report on Carcinogens Division of the National Toxicology Program National Institute of Environmental Health Sciences U.S. Department of Health and Human Services This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally distributed by the National Toxicology Program. It does not represent and should not be construed to represent any NTP determination or policy. This Page Intentionally Left Blank Peer-Review Draft RoC Monograph on Antimony Trioxide 11/29/17 Foreword The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public. The Report on Carcinogens (RoC) is prepared in response to Section 301 of the Public Health Service Act as amended. The RoC contains a list of identified substances (i) that either are known to be human carcinogens or are reasonably anticipated to be human carcinogens and (ii) to which a significant number of persons residing in the United States are exposed.
    [Show full text]